Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin

Francesco Artom, Valerio Del Bono

DOI: https://doi.org/10.7175/cmi.v8i1S.954

Abstract

Clostridium difficile colitis is a substantial cause of in-hospital morbidity. Since the mortality attributable may be as high as 10%, a prompt and effective treatment is advisable. Fidaxomicin is a well-documented effective drug for the treatment of C. difficile colitis and it is particularly effective in the treatment of recurrences. We report a case of a 92-year-old woman with prolonged hospitalization and recurrent episodes (three in a three-month period) of C. difficile diarrhea. Each episode initially responded to vancomycin. However, after the third episode fidaxomicin was given, with a sustained response (5 months without further episodes). In this patient fidaxomicin was safe and effective in treating recurrence of C. difficile colitis. The use of fidaxomicin as a therapy of first episode of C. difficile colitis should be considered for those patients with a predictable high risk of recurrent C. difficile colitis.

Keywords

Clostridium; Vancomycin; Fidaxomicin; Recurrence; Colitis

Full Text

HTML PDF

References

  • To KB, Napolitano LM. Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategy. Surg Infect (Larchmt) 2014; 15: 490-502; http://dx.doi.org/10.1089/sur.2013.186
  • Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26; http://dx.doi.org/10.1111/1469-0691.12418
  • Eyre DW, Walker AS, Wyllie D, et al; Infections in Oxfordshire Research Database. Predictors of first recurrence of Clostridium difficile infection: implications of initial management. Clin Infect Dis 2012; 55 Suppl 2: S77-S87; http://dx.doi.org/10.1093/cid/cis356
  • Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31; http://dx.doi.org/10.1056/NEJMoa0910812
  • Cornely OA, Crook DW, Esposito R, et al; for the OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the U.S.A.: a double blind, non inferiority, randomized and controlled trial. Lancet Infect Dis 2012; 12: 281-9; http://dx.doi.org/10.1016/S1473-3099(11)70374-7
  • Giuliano S, Guastalegname M, Jenco M, et al. Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection. BMC Infect Dis 2014; 14: 475; http://dx.doi.org/10.1186/1471-2334-14-475
  • Guastalegname M, Russo A, Falcone M, et al. Candidemia subsequent infection due to Clostridium difficile: is there a link? Clin Infect Dis 2013; 57: 772-4; http://dx.doi.org/10.1093/cid/cit362
  • Chilton CH, Crowther GS, Freeman J, et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-62; http://dx.doi.org/10.1093/jac/dkt347
  • Khan FY, Elzouki AN. Clostridium difficile infection: a review of literature. Asian Pac J Trop Med 2014; 7S1: S6-S13; http://dx.doi.org/10.1016/S1995-7645(14)60197-8
  • Daniel A, Rapose A. The evaluation of Clostridium difficile infection (CDI) in a community hospital. J Infect Public Health 2014. pii: S1876-0341(14)00140-3 [Epub ahead of print]; http://dx.doi.org/ 10.1016/j.jiph.2014.08.002

Statistics

Abstract: 785 views
HTML: 1742 views
PDF: 562 views

Refbacks

  • There are currently no refbacks.